Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26092930 | 0.86 | CRBN (0.38) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL7010905 | 0.84 | USP2 (0.46) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL15447211 | 0.82 | DDB1 (0.47) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL18319196 | 0.81 | USP2 (0.43) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL2028457 | 0.80 | DDB1 (0.45) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL3918200 | 0.78 | NEK2 (0.54) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL12501315 | 0.77 | USP2 (0.47) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL29788227 | 0.77 | USP2 (0.45) | CRBNDDB1USP2SMN1; SMN2KDM4E | |
| SCHEMBL30082764 | 0.77 | LMNA (0.46) | SMN1; SMN2KDM4EMAPT | |
| SCHEMBL9950025 | 0.77 | CRBN (0.43) | CRBNDDB1USP2SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119487029-A | N6-adenosyl-methyltransferase PROTAC and methods of use thereof | 苏黎世大学 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024107763-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024107763-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | UNIVERSITY OF ZURICH (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-20240139189-A1 | N6-ADENOSINE-METHYLTRANSFERASE INHIBITORS IN CANCER TREATMENT | UNIVERSITY OF ZURICH (CH) | 2024-05-02 | — | — | US | disclosed |
| CN-117715911-A | N6-adenosyl-methyltransferase inhibitors in the treatment of cancer | 苏黎世大学 | 2024-03-15 | — | — | CN | disclosed |
| WO-2023222762-A1 | N6-ADENOSINE-METHYLTRANSFERASE PROTACS AND METHODS OF USE THEREOF | UNIVERSITY OF ZURICH (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-9908897-B2 | Spirocyclic derivatives | CHRONOS THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-9908897-B2 | Spirocyclic derivatives | CHRONOS THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| EP-3201195-A1 | SPIROCYCLIC DERIVATIVES | Chronos Therapeutics Limited (GB) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016042452-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042452-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139189-A1 | N6-ADENOSINE-METHYLTRANSFERASE INHIBITORS IN CANCER TREATMENT | NNMT, MTAP, RNMT | CRBN 1027/4885DDB1 110/4885USP2 303/4885 |
| US-20170253615-A1 | Spirocyclic derivatives | SLC6A3, SLC10A1, ABCB11 | CRBN 2819/4885DDB1 2526/4885USP2 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.